Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
← catalyst calendarNCT06598306 · readout in 247 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →. With BeOne Medicines.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
220estimated
Sites
31
Countries
Australia, Belgium, China +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-07 | actual | When the study began enrolling |
| Primary completion | 2027-04-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-04-24 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Extensive Stage Small Cell Lung Cancer
Intervention
- Drug: Tarlatamab — also filed as AMG 757, Imdelltra
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Dose-limiting toxicities (DLTs)
measured Up to day 21
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to approximately 24 months
Number of Participants with Changes in Vital Signs
measured Up to approximately 24 months
Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests
measured Up to approximately 24 months
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed